Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients 06-29-2020 Akero Therapeutics to Announce New Data from NASH Phase 2a BALANCED Study of AKR-001 Headquarters Akero Therapeutics 601 Gateway Boulevard, Suite 350 South San Francisco, CA 94080 (650) 487-6488. The Investor Relations website contains information about Akero Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. Our lead product, AKR-001, mimics the biological activity of FGF21 to address an array of causes and pathological processes underlying development of NASH. AKRO shares opened 40% higher today at $35.10 (+$10.18, +40.85%) over yesterday's $24.92 closing price and reached a new 52-week high price this morning of $35.30. Find the latest Akero Therapeutics, Inc. (AKRO) stock quote, history, news and other vital information to help you with your stock trading and investing. Contact Email info@akerotx.com Akero Therapeutics is committed to providing meaningful treatment options for people with serious metabolic diseases like non-alcoholic steatohepatitis (NASH), a disease marked by inflammation in the liver and liver cell damage … Home Mail Akero Therapeutics is developing pioneering medicines designed to restore metabolic balance and halt NASH progression. Akero Therapeutics is developing pioneering medicines designed to restore metabolic balance and halt NASH progression.Our lead product, AKR-001, mimics the biological activity of FGF21 to address an array of causes and pathological processes underlying development of NASH.Akero Therapeutics is developing pioneering medicines designed to restore metabolic balance and halt NASH progression.Our lead product, AKR-001, mimics the biological activity of FGF21 to address an array of causes and pathological processes underlying development of NASH.© 2020 Akero Therapeutics, Inc. All rights reserved. Currency in USD Akero Therapeutics started the trading day with a market capitalization of around $714.6 million with approximately 28.67 million shares outstanding. Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed … Media Contact Carolyn Hawley | Canale Communications Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, today reported second quarter financial results for the period ending June 30, 2020.Investing legend Whitney Tilson says there's a huge new tech trend coming – and he's revealing his #1 pick for free.French biotech Genfit, which had been expected to bring one of the first drugs to market to treat nonalcoholic steatohepatitis, said it is getting out of the race altogether.Market Update: BKNG, GOLD, CLS, MO, MRK, FBHS, ZTS, CTVADiscover new investment ideas by accessing unbiased, in-depth investment researchNasdaqGS - NasdaqGS Real Time Price.